GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6360
- Registration Number
- NCT00139347
- Locations
- 🇵🇦
GSK Investigational Site, Panama, Panama
Michelangelo - Oasis 5
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20078
- Registration Number
- NCT00139815
Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 250
- Registration Number
- NCT00137930
- Locations
- 🇫🇮
GSK Investigational Site, Turku, Finland
Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 478
- Registration Number
- NCT00137917
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 617
- Registration Number
- NCT00136604
- Locations
- 🇹🇭
GSK Investigational Site, Songkla, Thailand
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00136578
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom
SB-743921 In Patients With Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00136513
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT00135486
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT00135564
Study Of Generalized Anxiety Disorder
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00135525
© Copyright 2024. All Rights Reserved by MedPath